These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37625930)

  • 1. Translational implications of newly characterized pathogenic pathways in systemic lupus erythematosus.
    Gatto M; Depascale R; Stefanski AL; Schrezenmeier E; Dörner T
    Best Pract Res Clin Rheumatol; 2023 Dec; 37(4):101864. PubMed ID: 37625930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
    Chyuan IT; Tzeng HT; Chen JY
    Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and future therapies: Changes in the therapeutic armamentarium for SLE.
    Askanase A; Khalili L; Tang W; Mertz P; Scherlinger M; Sebbag E; Chasset F; Felten R; Arnaud L
    Best Pract Res Clin Rheumatol; 2023 Dec; 37(4):101865. PubMed ID: 37633826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells targeting therapy in the management of systemic lupus erythematosus.
    Lee WS; Amengual O
    Immunol Med; 2020 Mar; 43(1):16-35. PubMed ID: 32107989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunopathogenesis of systemic lupus erythematosus: An update.
    Arnaud L; Chasset F; Martin T
    Autoimmun Rev; 2024 Oct; 23(10):103648. PubMed ID: 39343084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting interferons and their pathways in systemic lupus erythematosus.
    Chasset F; Arnaud L
    Autoimmun Rev; 2018 Jan; 17(1):44-52. PubMed ID: 29108825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic avenues in SLE.
    Bakshi J; Ismajli M; Rahman A
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):794-809. PubMed ID: 27107514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus.
    Catalina MD; Owen KA; Labonte AC; Grammer AC; Lipsky PE
    J Autoimmun; 2020 Jun; 110():102359. PubMed ID: 31806421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies.
    Fetter T; Wenzel J
    Exp Dermatol; 2020 Nov; 29(11):1123-1132. PubMed ID: 32633821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
    Sthoeger Z; Sharabi A; Mozes E
    J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.
    Jordan N; Lutalo PM; D'Cruz DP
    Immunotherapy; 2015; 7(3):255-70. PubMed ID: 25804478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological pathogenesis and treatment of systemic lupus erythematosus.
    Pan L; Lu MP; Wang JH; Xu M; Yang SR
    World J Pediatr; 2020 Feb; 16(1):19-30. PubMed ID: 30796732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are lupus animal models useful for understanding and developing new therapies for human SLE?
    Moore E; Putterman C
    J Autoimmun; 2020 Aug; 112():102490. PubMed ID: 32535128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of viral infection and B cells as a linker between innate and adaptive immune response in systemic lupus erythematosus.
    Ghobadi MZ; Izadi S; Teymoori-Rad M; Farahmand M; Mozhgani SH; Labbaf N; Shokri F; Marashi SM
    Immunol Res; 2021 Apr; 69(2):196-204. PubMed ID: 33786699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
    Bela MM; Espinosa G; Cervera R
    Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
    [No Abstract]   [Full Text] [Related]  

  • 19. [Systemic lupus erythematosus: from pathophysiology to treatment].
    Contin-Bordes C; Lazaro E; Pellegrin JL; Viallard JF; Moreau JF; Blanco P
    Rev Med Interne; 2009 Dec; 30(12 Suppl):H9-13. PubMed ID: 19995652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials.
    Felten R; Dervovic E; Chasset F; Gottenberg JE; Sibilia J; Scher F; Arnaud L
    Autoimmun Rev; 2018 Aug; 17(8):781-790. PubMed ID: 29885544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.